- Home
- NRXP vs PULM Comparison
NRXP vs PULM Comparison
Compare NRXP & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- PULM
- Stock Information
- Founded
- NRXP 2015
- PULM 2003
- Country
- NRXP United States
- PULM United States
- Employees
- NRXP N/A
- PULM N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- PULM Health Care
- Exchange
- NRXP Nasdaq
- PULM Nasdaq
- Market Cap
- NRXP 32.6M
- PULM 33.2M
- IPO Year
- NRXP N/A
- PULM N/A
- Fundamental
- Price
- NRXP $3.02
- PULM $6.19
- Analyst Decision
- NRXP Strong Buy
- PULM
- Analyst Count
- NRXP 4
- PULM 0
- Target Price
- NRXP $28.50
- PULM N/A
- AVG Volume (30 Days)
- NRXP 187.5K
- PULM 50.1K
- Earning Date
- NRXP 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- NRXP N/A
- PULM N/A
- EPS Growth
- NRXP N/A
- PULM N/A
- EPS
- NRXP N/A
- PULM N/A
- Revenue
- NRXP N/A
- PULM $1,921,000.00
- Revenue This Year
- NRXP N/A
- PULM N/A
- Revenue Next Year
- NRXP N/A
- PULM $134.88
- P/E Ratio
- NRXP N/A
- PULM N/A
- Revenue Growth
- NRXP N/A
- PULM N/A
- 52 Week Low
- NRXP $1.10
- PULM $1.78
- 52 Week High
- NRXP $6.01
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- NRXP 43.71
- PULM 38.00
- Support Level
- NRXP $2.89
- PULM $6.06
- Resistance Level
- NRXP $3.53
- PULM $6.49
- Average True Range (ATR)
- NRXP 0.15
- PULM 0.30
- MACD
- NRXP -0.06
- PULM -0.03
- Stochastic Oscillator
- NRXP 18.97
- PULM 1.27
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).